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Background: Malignant melanoma is an aggressive tumor type that often develops drug resistance to targeted
therapeutics. The production of colony stimulating factor 1 (CSF-1) in tumors recruits myeloid cells such as M2-polarized
macrophages and myeloid derived suppressor cells (MDSC), leading to an immune suppressive tumor milieu.
Methods: We used the syngeneic mouse model of BRAFV600E-driven melanoma SM1, which secretes CSF-1, to evaluate
the ability of the CSF-1 receptor (CSF-1R) inhibitor PLX3397 to improve the antitumor efficacy of the oncogenic BRAF
inhibitor vemurafenib.
Results: Combined BRAF and CSF-1R inhibition resulted in superior antitumor responses compared with either therapy
alone. In mice receiving PLX3397 treatment, a dramatic reduction of tumor-infiltrating myeloid cells (TIM) was observed.
In this model, we could not detect a direct effect of TIMs or pro-survival cytokines produced by TIMs that could confer
resistance to PLX4032 (vemurafenib). However, the macrophage inhibitory effects of PLX3397 treatment in combination
with the paradoxical activation of wild type BRAF-expressing immune cells mediated by PLX4032 resulted in more
tumor-infiltrating lymphocytes (TIL). Depletion of CD8+ T-cells abrogated the antitumor response to the combination
therapy. Furthermore, TILs isolated from SM1 tumors treated with PLX3397 and PLX4032 displayed higher immune
potentiating activity.
Conclusions: The combination of BRAF-targeted therapy with CSF-1R blockade resulted in increased CD8 T-cell
responses in the SM1 melanoma model, supporting the ongoing evaluation of this therapeutic combination in patients
with BRAFV600 mutant metastatic melanoma.
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Targeted therapies such as the oncogenic BRAF inhibitor
PLX4032 (with generic drug name vemurafenib) has re-
sulted in high response rates and improved overall sur-
vival in patients with melanoma. However, consistent
with other oncogene-targeted therapies, initial patient
response is of limited durability and tumors eventually
relapse [1-4].
Overcoming the immunosuppressive tumor micro-
environment mediated by growth factor and receptor
tyrosine kinases (RTK) have been of particular interest* Correspondence: aribas@mednet.ucla.edu
1Department of Molecular and Medical Pharmacology, University of
California Los Angeles (UCLA), Los Angeles, CA, USA
2Department of Surgery, Division of Surgical Oncology, University of
California Los Angeles (UCLA), Los Angeles, CA, USA
Full list of author information is available at the end of the article
© 2015 Mok et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.in cancer therapy. Tumor cells manipulate the surroun-
ding milieu by producing cytokines that suppress cyto-
lytic T-cells and recruit immunosuppressive cells [5-7].
Colony stimulating factor 1 (CSF-1) is one such cytokine
secreted by several cancer cell types, including melan-
oma [8,9]. It induces the proliferation and differentiation
of immunosuppressive myeloid cells such as M2 pola-
rized macrophages and myeloid derived suppressor cells
(MDSC) by binding to the CSF-1 receptor (CSF-1R) on
the cell surface [5,10,11]. Therefore, the immunosup-
pressive tumor milieu mediated by CSF-1 helps tumor
cells escape immune responses and metastasize.
In prior studies, we developed the SM1 cell line from
transgenic mice with melanocyte-restricted expression of
the BRAFV600E mutation. SM1 is a murine melanoma
model syngeneic to immunocompetent mice. In additionis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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genomic aberrations and share overall similarity to a
panel of 108 human melanoma cell lines based on copy
number alteration profiling. In this model, we observed
that adoptive cell transfer (ACT) of melanoma-targeted
T-cells induces antitumor responses that are augmented by
the BRAF inhibitor PLX4032. Treatment with PLX4032 in-
duces paradoxical activation on TILs, resulting in increased
cytotoxic activity and IFN-γ production [12]. These fin-
dings provide a potential explanation as to why host im-
munity is a key component of the antitumor activity of
BRAF inhibitors [13]. However, the SM1 model is an
aggressive model in which control mice with established
tumors need to be sacrificed within two to three weeks.
Accordingly, tumors could not be fully eradicated when
immunotherapy was combined with PLX4032. In addition,
our previous work demonstrated that SM1 cells secrete
cytokines such as CSF-1 that binds to CSF-1R on myeloid
cells to recruit and promote the differentiation of myeloid
cells into immunosuppressive M2-polarized macrophages.
On the therapeutic front, we report that PLX3397, a po-
tent tyrosine kinase inhibitor that targets CSF-1R, inhibits
the immunosuppressive tumor milieu and facilitates im-
mune responses, resulting in improved antitumor T-cell
function [14].
In this report, we demonstrate that the combination of
PLX4032 and PLX3397 mediates superior antitumor re-
sponses compared with either single treatment alone.
PLX3397 treatment blocked the recruitment of TIMs
and increased the number of TILs. We observed that full
antitumor efficacy of PLX4032 required an intact im-
mune system. Taken together, our data support a model
in which inhibition of CSF-1/CSF-1R signaling can aug-
ment the antitumor effect of BRAF targeted therapy.
Based on our results in the SM1 model, we provide
preclinical support for the therapeutic combination of
BRAF and CSF-1R inhibition currently being tested in
patients with BRAFV600 mutant metastatic melanoma
(trial NCT01826448).
Methods
Mice, cell lines and reagents
C57BL/6 mice and NOD/SCID/γ chainnull (NSG) mice
(NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ, Jackson Laboratory, Bar
Harbor, ME) were bred and kept under defined-flora
pathogen-free conditions at the AALAC-approved animal
facility of the Division of Experimental Radiation Oncology,
UCLA, and used under the UCLA Animal Research Com-
mittee protocol #2004-159. The SM1 murine melanoma
was generated from a spontaneously arising tumor in
BRAFV600E mutant transgenic mice as previously described
[15]. SM1 was maintained in RPMI (Mediatech, Herndon,
VA) with 10% FCS (Omega Scientific), 2 mM L-glutamine
(Invitrogen, Carlsbad, CA) and 1% penicillin, streptomycinand amphotericin. Immortalized macrophages I-11.15
were obtained from ATCC and were maintained as pre-
viously described [16]. PLX3397 and PLX4032 were ob-
tained under a materials transfer agreement (MTA) with
Plexxikon Inc. (Berkeley, CA). PLX3397 was dissolved in
dimethyl sulfoxide (DMSO, Fisher Scientific, Morristown,
NJ) for in vitro use. For in vivo studies, PLX3397 was dis-
solved in DMSO, and then a suspension made by dilution
into an aqueous mixture of 0.5% hydroxypropyl methyl
cellulose (HPMC) and 1% polysorbate (PS80) (Sigma-
Aldrich). 100 μL of the suspended drug was administered
by daily oral gavage into mice at 50 mg/kg when tumors
reached 5 mm in diameter. PLX4032 was dissolved in
DMSO, and used for in vitro studies as previously de-
scribed [17]. For in vivo studies, it was dissolved in
DMSO, followed by PBS (100 μL), which was then
injected daily intraperitoneally (i.p) into mice at a dose of
100 mg/kg. For antibody-mediated depletion studies,
250 μg of anti-CD8 antibody, or isotype control antibody
(BioXCell, West Lebanon, NH) was injected i.p. every
3 days.
Cell viability assays
SM1 cells (5 × 103 cells/well) were seeded on 96-well flat-
bottom plates with 100 μL of 10% FCS media and incu-
bated for 24 hours. PLX4032 or DMSO vehicle control
with graded dilutions of hepatocyte growth factor (HGF) or
tumor necrosis factor-α (TNF-α) (PeproTech), in culture
medium, were added to each well in triplicate and analyzed
by using tetrazolium compound [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS)-based colorimetric cell proliferation
assay (Promega, Madison, WI).
Bioluminescence assay
SM1 cells were lentivirally transduced to express firefly
luciferase and used for co-culturing with macrophages.
Bioluminescence assays were carried out with a DTX880
Multimode Detector (Beckman Coulter).
Flow cytometry analysis and cell sorting
SM1 tumors were harvested from mice and further di-
gested with collagenase (Sigma-Aldrich). Cells obtained
form digested SM1 tumors were stained with antibodies
to CD3, CD8 (BD Biosciences) for TILs or antibodies to
F4/80, CD11b for TIMs and analyzed with a LSR-II or
FACSCalibur flow cytometer (BD Biosciences), followed
by Flow-Jo software (Tree-Star, Ashland, OR) analysis as
previously described [12,14].
Immunofluorescence imaging
Staining was performed as previously described [15].
Briefly, sections of OCT (Sakura Finetek, Torrance, CA)
cryopreserved tissues were blocked in donkey serum/
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(Abcam) or CD8 (BD Biosciences), followed by second-
ary donkey anti-rat antibodies conjugated to DyLight488
(Jackson Immunoresearch Laboratories, West Grove,
PA). Negative controls consisted of isotype matched rab-
bit or rat IgG in lieu of the primary antibodies listed
above. DAPI (4,6-diamidino-2-phenylindole) was used for
the visualization of nuclei. Immunofluorescence images
were taken in a fluorescence microscope (Axioplan-2; Carl
Zeiss Microimaging, Thornwood, NY).
Intratumoral myeloid cell isolation
SM1 tumors previously established in C57BL/6 mice
were harvested and further digested with collagenase
(R&D System). Intratumoral myeloid cells were isolated
from digested tumor using CD11b + cell isolation kit
(Miltenyi).
Microarray data generation and analysis
Total RNAs were extracted using the RNeasy MicroKit
(Qiagen) from SM1 tumors, FACS-sorted macrophages,
and T-cells. Yield of RNA was amplified using RNA
Amplification System (NuGEN). cDNAs were generated,
fragmented, biotinylated, and hybridized to the Gene-
Chip Mouse 430 V2 Arrays (Affymetrix). The arrays
were washed and stained on a GeneChip Fluidics Station
450 (Affymetrix); scanning was carried out with the
GeneChip Scanner 3000 7G; and image analysis with the
Affymetrix GeneChip Command Console Scan Control.
Microarray analyses were performed in the R statistical
programming environment and using Bioconductor
suite of packages [18]. Expression data were normalized,
background-corrected, and summarized using the Robust
Multi-Array Average (RMA) algorithm implemented in
the R ‘affy’ package [19]. Two to three replicates were pre-
pared per treatment group. Expression level of each gene
was averaged among samples and used for further ana-
lysis. Differential expression was computed using the
R ‘limma’ package [20]. Hierarchical clustering was per-
formed using the Euclidean distance as the similarity
metric with average linkage clustering. Clustering results
were visualized by heat maps generated using the R ‘NMF’
package [21].
Rank-rank hypergeometric overlap (RRHO) analysis
Gene expression profiles of monocytes and T-cells were
obtained from a reference immune cell signature database,
the Differentiation Map Portal (DMAP) [22]. Human gene
annotations were converted to mouse gene annotations
using the NCBI HomoloGene database. Gene-expression
profiles from the two data sets were compared by ranking
genes measured in the two experiments according to their
signed log10 p-value of differential expression between
class A and class B. RRHO heat maps that graphically andstatistically visualize correlations between two expression
profiles were generated at http://systems.crump.ucla.edu/
rankrank/ [23].
Gene ontology enrichment analysis
Gene ontology enrichment analysis was performed on
genes with a log2 fold change greater than 2.0 in the
combo treated groups using the GOTermFinder tool from
http://go.princeton.edu/cgi-bin/GOTermFinder [24]. Top
significantly enriched terms as determined by Bonferroni
corrected p-values were reported.
Statistical analysis
Data were analyzed with GraphPad Prism (version 5)
software (GraphPad Software, La Jolla, CA). A Mann–
Whitney test or ANOVA with Bonferroni post-test was
used to analyze experimental data. Survival curves were
generated by actuarial Kaplan–Meier method and ana-
lyzed with the Jump-In software (SAS) with log-rank test
for comparisons from the time of tumor challenge to
when mice were sacrificed due to tumors reaching
14 mm in maximum diameter, or when the end of the
study period had been reached.
Results
Combined therapy with PLX3397 and PLX4032 improves
antitumor responses against SM1 tumors
C57BL/6 mice with established subcutaneous SM1 tu-
mors were treated with the CSF-1R inhibitor PLX3397
and the BRAF inhibitor PLX4032 daily once tumor
diameter reached ~5 mm (Figure 1a). The combined
therapy of PLX3397 and PLX4032 demonstrated supe-
rior antitumor effects compared to either therapy alone
in duplicate experiments and improved overall survival
(Figure 1b and c). Mice in either of the single or com-
bined treatment groups had high drug tolerability as de-
termined by no significant weight loss (data not shown).
Decrease in tumor infiltrating macrophages by PLX3397
and PLX4032
To test whether PLX3397 and PLX4032 changed the
number of TIMs such as macrophages, we analyzed
their presence in tumors by immunofluorescence. The
results corresponded to our previous findings of a dra-
matic decrease in the quantity of F4/80(+) macrophages
in both the PLX3397 single agent group and the com-
bined group compared to vehicle control [14]. PLX4032
slightly decreased the number of macrophages in the
tumor (Figure 2a), in agreement with previous reports
[13,25,26].
Effects of macrophages on SM1 cells
It has been reported that some cell types in the tumor
























PLX3397 + PLX4032 
C57B/6 mice 
i m p l a n t e d 








Both treatments start 
























Figure 1 Combined antitumor activity of PLX3397 and PLX4032 in murine melanoma SM1 model. a) Schematic of PLX3397 and PLX4032
treatments in C57BL/6 mice with previously established SM1 tumors. b) Tumor growth curves of established SM1 in C57BL/6 mice through day
28 post-tumor implantation. On day 12, the differences between vehicle and PLX3397: p = 0.0000004; PLX3397 and PLX4032: p = 0.000000009;
PLX4032 and combo: p = 0.000001. c) Kaplan–Meier actuarial plot of time to mouse sacrifice due to large tumor burden or to study termination
when tumor size was less than 14 mm in maximum diameter.
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tumor necrosis factor-α (TNF-α) resulting in resistance
to BRAF inhibition [27-29]. A potential mechanism to
explain the improved antitumor activity of combining
PLX3397 with PLX4032 is that PLX3397 depletes mac-
rophages, which secrete pro-survival growth factors, and
thus increases the sensitivity of SM1 tumor cells to
PLX4032. To test this hypothesis, SM1 cells were trans-
duced to express firefly luciferase and co-cultured with
intratumoral myeloid cells obtained from mice. We tes-
ted whether the presence of TIMs could increase proli-
feration of SM1 by producing secreted factors that
would foster melanoma cell growth. However, we found
that the co-cultured myeloid cells did not directly in-
crease SM1 proliferation (Figure 2b). Furthermore, in
this context PLX3397 did not increase sensitivity of SM1
cells to PLX4032 (Figure 2c). We next repeated this
experiment using an immortalized macrophage cell line,
I-11.15, in which macrophage cell growth is dependent
on secreted CSF-1. Again, co-culture with I-11.15 cells
did not increase proliferation of SM1 nor protect it from
PLX4032 (Figure 2d and e). In order to further test if se-
creted growth factors mediate resistance to BRAF inhi-
bition, SM1 cells were cultured with HGF or TNF-α and
treated with PLX4032. Using a MTS-based assay todetermine cell viability, we found that neither of these
cytokines mediated resistance to PLX4032 (Figure 2f ).
From these studies, we concluded that the direct effect
of TIMs or pro-survival cytokines produced by TIMs
did not confer resistance to PLX4032.
PLX3397 increases the expansion of intratumoral
lymphocytes
The amount of TILs in SM1 tumors was first analyzed by
immunofluorescence of tumor sections. CD8(+) TILs
were present at a low level in tumors from vehicle and
PLX4032 single treatment groups and at high levels in the
PLX3397 and combined treatment groups (Figure 3a). To
better enumerate the magnitude and distribution of TILs
in vivo, we analyzed their presence in tumors by flow
cytometry. Consistent with the immunofluorescence data,
there was an increase in the quantity of CD3(+) TILs
following treatment with PLX3397 (Figure 3b and c).
The antitumor activity of PLX3397 + PLX4032 is
T-cell-dependent
Since PLX3397 treatment increased the number of TILs
compared to vehicle control (Figure 3a, b, and c), we tested
the role of immune cells in the antitumor activity of



















































































































































































Figure 2 Changes in intratumoral macrophages in responses to PLX3397 and PLX4032. a) C57BL/6 mice with SM1 tumors were treated with PLX3397
and PLX4032 for 5 days. Tissue immunofluorescence microscopy of tumor sections was used to assess prolonged effects of the drug on macrophages.
Representative H&E (left) and immunofluorescence for macrophages stained with anti-F4/80-FITC (green, right), and nuclei stained with DAPI (blue, right).
b) Effect of macrophages on SM1 cells. Bar-graph representation of bioluminescence activity of SM1 cells. SM1 cells were transduced with a lentivirus-firefly
luciferase and co-cultured with and without intratuoral myeloid cells isolated from SM1 tumors (1:3 ratio) for 72 hours. Difference between SM1-luc and
SM1-luc + TIMs: p = 0.4 c) SM1 cells co-cultured with myeloid cells (1:3 ratio) were treated with 1 μM PLX3397, 15 μM PLX4032, or in combination for
72 hours. Difference between vehicle and PLX3397: p = 0.83; PLX3397 and PLX4032: p = 0.0001; PLX4032 and combo: p = 0.39. d) SM1 cells expressing
firefly luciferase were co-cultured with I-11.15 (1:3 ratio). Difference between SM1-luc and SM1-luc + I-11.15: p = 0.6. e) SM1-luc cells co-cultured with I-11.15
were treated with 1 μM PLX3397, 15 μM PLX4032, or in combination for 72 hours. Difference between vehicle and PLX3397: p = 0.05; PLX3397 and
PLX4032: p = 0.0002; PLX4032 and combo: p = 0.7. f) Effect of growth factors on SM1 to PLX4032. SM1 cells were exposed to 15 μM PLX4032 with HGF or
TNF-α (25 or 50 ng/mL). Cell viability assay (MTS) was performed after 72 hours. Difference between vehicle and PLX4032: p = 0.004; PLX4032 and PLX4032 +
HGF (50 ng/mL): p = 0.06; PLX4032 and PLX4032 + TNF-α (50 ng/mL): p = 0.12.



























































Figure 3 Changes in tumor infiltrating lymphocytes in responses to PLX3397 and PLX4032. a) C57BL/6 mice with SM1 tumors were treated with
PLX3397 and PLX4032 for 5 days. Tissue immunofluorescence microscopy of tumor sections was used to determine effect of the drugs on lymphocytes.
Representative H&E (left) and immunofluorescence for lymphocytes stained with anti-CD8-FITC (green, right), and nuclei stained with DAPI (blue, right).
b) Cells stained for CD3 were used for FACS analysis. Bar-graph representation of percentage of CD3+ T-cells in tumors. c) Representative FACS plots
demonstrating percentages of CD3+ T-cells in tumor tissue.
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PLX4032. In these immunodeficient mice, there was no an-
titumor activity of PLX3397 compared to mice receiving
vehicle control. Furthermore, the tumor growth curve of
the combined treatment group overlapped with the
PLX4032 alone group (Figure 4a). Surprisingly, tumor
growth of SM1 tumors in the PLX4032 alone group was
much faster in NSG mice than C57BL/6 mice, supporting
the possibility that the full antitumor effect of PLX4032 re-
quires an intact immune system (Figures 1b and 4a). In
order to further determine if endogenous cytotoxic CD8+
T-cells mediated the antitumor activity of the combined
treatment group, we depleted CD8+ cells using anti-CD8
antibody therapy in C57BL/6 mice implanted with SM1 tu-
mors and receiving PLX3397 and PLX4032. The depletion
of CD8+ cells abrogated the antitumor activity of the com-
bined treatment group (Figure 4b). Collectively, these stud-
ies highlight the role of CD8+ T-cells as effectors of the
antitumor activity of PLX3397 and PLX4032 in the SM1
murine melanoma model.PLX3397 and PLX4032 increase functional activation of
intratumoral lymphocytes and suppress myeloid cells
In two prior reports [12,14], we have demonstrated that
PLX4032 increased cytotoxicity and the cytokine produc-
tion function of T-cells, while PLX3397 enhanced T-cell
cytokine production and infiltration into tumors. In
order to better understand the impact of PLX3397 and
PLX4032 on T-cell activation and macrophage sup-
pression, we compared the gene expression profile of SM1
tumors following treatments with PLX3397, PLX4032, or
combination treatment for 5 days. Using a gene signature
overlap analysis (Rank-Rank Hypergeometric Overlap,
RRHO) and a reference immune cell signature database
(Differentiation Map, DMAP), we analyzed the presence
of T-cell and monocytes gene signatures in each tumor
treatment group compared with vehicle control [22,23].
The signature comparison analysis identified that the
drug-treated tumors expressed T-cell signatures, while the
vehicle-treated tumors expressed stronger monocyte sig-




















































Figure 4 Lack of superior antitumor activity of PLX3397 and PLX4032 in immunodeficient mice or with CD8+ T-cell depletion. a) Tumor growth
curves of established SM1 tumors in NSG mice treated with PLX3397 and PLX4032. b) SM1 tumor-bearing mice treated with PLX3397 and PLX4032
received anti-CD8 depleting antibody. On day 16, the differences between vehicle and anti-CD8 depletion group: p = 0.15; anti-CD8 depletion group
and triple combination: p = 0.0000001; triple combination and PLX4032: p = 0.0000001; PLX4032 and combo: p = 0.000006.
Mok et al. BMC Cancer  (2015) 15:356 Page 7 of 10PLX3397 and PLX4032 combined treatment groups had
increased T-cell infiltration and decreased monocyte cell
presence or activity in the tumor. Of note, there was no
significant difference in this signature analysis between
the single drug treatment groups and the combined drug
treatment group.
In order to specifically determine the expression level
of genes in tumor-associated macrophages and T-cells,
F4/80(+) CD11b(+) macrophages and CD3(+) CD8(+)
T-cells were FACS sorted from SM1 tumors. Tumors were
either treated with vehicle, PLX3397 and/or PLX4032 for
5 days. RNA was extracted and used for microarray gene
expression analysis. Since IFN-γ provides a general assess-
ment of T-cell immune activation, the expression values
of IFN-γ was used as a quality control for this study
(Additional file 1: Figure S1c). We found that M2-
polarized macrophage-related genes reported previously
[30,31], such as Arg1, IL-10, CD163, and MSR1 were
down-regulated in each of the drug-treatment groups
(Figure 5d). In contrast, genes, such as IFN-γ, Irg1, and
Gbp1 that are associated with an type I interferon response
were up-regulated in macrophages in both PLX3397 and
PLX4032 treatment groups (Additional file 1: Figure S1a;Table S1) [32]. Using gene ontology-based enrichment
analysis, we found that the genes most substantially down-
regulated in macrophages were associated with angio-
genesis and vasculature development (Additional file 1:
Figure S1b; Table S2). We also observed that PLX3397,
PLX4032 and combined treatment led to an improved
T-cell activation signature. For example, T-cell activation-
associated genes such as IFN-γ, Gzmb, Pdcd1 were up-
regulated in T-cells in response to all drug treatments
(Figure 5e; Additional file 1: Figure S1c) [33,34]. Collec-
tively, our data suggests that PLX3397 and PLX4032 not
only down-regulate M2-polarized macrophage associated
genes, but also induce a skewing toward M1-type macro-
phages that results in increased T-cell activation.
Discussion
The high initial antitumor efficacy of BRAF inhibitors is
limited by the short durability of responses. Engaging an
immune response may merge the benefits of the high
response rates of BRAF inhibitors and the long-term
response durability of immunotherapy [35]. Our data
support the combination of CSF-1R inhibition with
PLX4032 and provide a strong rationale to translate
-2 
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Figure 5 In vivo T-cell activation and suppression of macrophages mediated by PLX3397 and PLX4032. Gene expression signature overlap maps
were used to compare the similarity of drug-treated full tumor gene expression profiles with a panel of T-cell and monocyte (Mono) gene signatures
from a reference immune cell signature database (the Rank-Rank Hypergeometric Overlap (RRHO) algorithm and the Differentiation Map (DMAP)
database), a) PLX3397 treatment vs vehicle control (VC); b) PLX4032 vs vehicle; c) combined drug treatment (Combo) vs vehicle. d) Gene expression
heat map for macrophage signature genes in F4/80(+) CD11b(+) macrophages FACS-sorted from SM1 tumors treated with PLX3397 or PLX4032 for
5 days. e) Gene expression heat map for T-cell signature genes in CD3(+) CD8(+) T-cells from SM1 tumors. Color scale, log2-transformed fold change
expression (red, high; green, low) for each gene (row) normalized to the value for the vehicle control-treated tumors.
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cells for patients with BRAFV600 mutant metastatic mel-
anoma. The scientific rationale for this combination is
based on our results from two previous reports [12,14]
using a murine melanoma model SM1 that has the
BRAFV600E mutation. Besides causing apoptosis and cell
cycle arrest in BRAFV600E mutant melanoma cells, in
BRAF wild type cells PLX4032 has also been shown to
have the paradoxical effect of activating the MAPK path-
way through the transactivation of CRAF by a partially
blocked wild-type CRAF-BRAF dimer. This results in in-
creased T-cell activation with increased cytotoxic activity
and intratumoral cytokine secretion from TILs [12,36,37].
At the same time, PLX3397 has been demonstrated toincrease the number of TILs with enhanced IFN-γ secret-
ing function [14]. Here we found the combination of both
pharmacologic interventions augments the individual anti-
tumor effects.
We explored the potential mechanisms by which
PLX3397 improves the antitumor effect of PLX4032
using the SM1 melanoma tumor model. Our studies
showed that PLX3397 dramatically depleted macrophages
in the tumor microenvironment and PLX4032 slightly de-
creased the number of macrophages, likely due to down-
regulation of secreted cytokines such as CCL2 that could
recruit immunosuppressive cells [13]. Furthermore, we
noted an increase in the number of TILs in tumors treated
with PLX3397. Depletion of CD8+ T-cells in mice
Mok et al. BMC Cancer  (2015) 15:356 Page 9 of 10abrogated the superior antitumor effect of the combined
therapy, providing support for the role of T cells in the ob-
served antitumor effect. Furthermore, TILs from either
PLX3397 or PLX4032 treatment groups had higher func-
tional activation with increased ability to release the
immune-stimulating cytokine IFN-γ compared to the un-
treated group. The immune-activating effects mediated by
PLX4032 can be explained by the paradoxical activation of
MAPK pathway in T-cells that are wildtype for BRAF,
while the immune response mediated by PLX3397 is
explained by the depletion of an immunosuppressive en-
vironment. Therefore, the major beneficial effects of com-
bining PLX3397 and PLX4032 in SM1 are derived from
increasing the infiltration of functionally activated T-cells
into the tumor, in addition to the direct antitumor effect
of PLX4032 on the BRAFV600E mutant tumor.
Myeloid and other cells of the tumor microenviroment
can produce factors that confer resistance to targeted
therapies. This is of particular importance when using
BRAF inhibitors, since it has been shown that stromal
cells secreting HGF or TNF-α can reactivate the MAPK
and PI(3)K-AKT signaling pathways to cause resistance
to RAF inhibition [27-29]. However, in our studies we
could not readily demonstrate any protective effects of
myeloid cell co-culture on SM1 cells with regards to
sensitivity to PLX4032. We also directly tested the pro-
tective effects of growth factor ligands by treating SM1
cells exposed to PLX4032 with cytokines. However, these
cytokines did not decrease the SM1 cell sensitivity to
BRAF inhibitors. Thus, the previously observed growth
factor-mediated effect on PLX4032 sensitivity may be
tumor model dependent.
SM1 is a cell line that is relatively resistant to PLX4032
(IC50 ≈ 15 μM) in vitro and accordingly it forms tumors
that are hard to eradicate in in vivo mouse models. Al-
though there is a rapid antitumor response with PLX4032,
tumors nonetheless progress over time and mice have to
be sacrificed within two to three weeks. The relative
PLX4032 resistance of SM1 cells may be tied to the mul-
tiple genomic alterations present in these cells, such as
deletion of CDKN2A and amplification of BRAFV600E and
MITF [12]. Hyper-activation of BRAFV600E has been
shown to be a mechanism of resistance to BRAF inhibitors
[38]. As additional murine melanoma BRAFV600E cell lines
and corresponding mouse models of melanoma are de-
veloped, the effects of PLX4032 combined with other
therapeutic agents such as CSF-1R inhibitors may lead to
stronger synergistic antitumor responses.
Conclusions
Combination therapy with the CSF-1R inhibitor PLX3397
and the oncogenic BRAF inhibitor vemurafenib result in
superior antitumor effects compared to single agent treat-
ment in a murine model of melanoma. The antitumoractivity is mediated by both i) the inhibition of the
immunosuppressive tumor microenvironment which in-
creases intratumoral lymphocyte infiltration, and ii) en-
hanced functionality of the infiltrating lymphocytes. This
data provides strong rationale for the continued clinical
testing of PLX3397 with vemurafenib in patients with
melanoma (as in trial NCT01826448).Additional file
Additional file 1: Table S1. Top up-regulated genes in macrophages in
combined treatment group with significant GO terms. Table S2. Top
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